Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions
Abolfazl Maghrouni, Maryam Givari, Mohammad Jalili‐Nik, et al.
International Immunopharmacology (2021) Vol. 93, pp. 107403-107403
Closed Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes
Dávid Sipos, Bence L. Raposa, Omar Freihat, et al.
Cancers (2025) Vol. 17, Iss. 1, pp. 146-146
Open Access | Times Cited: 2
RGD-engineered nanoparticles as an innovative drug delivery system in cancer therapy
Mehdi Sanati, Amir R. Afshari, Samaneh Aminyavari, et al.
Journal of Drug Delivery Science and Technology (2023) Vol. 84, pp. 104562-104562
Closed Access | Times Cited: 26
pH-Responsive Polyethylene Glycol Engagers for Enhanced Brain Delivery of PEGylated Nanomedicine to Treat Glioblastoma
Jun-Lun Meng, Dong Zhang, Yanru Chen, et al.
ACS Nano (2025)
Open Access | Times Cited: 1
Recent advances in glioblastoma multiforme therapy: A focus on autophagy regulation
Mehdi Sanati, Maryam Moradi Binabaj, Seyed Sajad Ahmadi, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 155, pp. 113740-113740
Open Access | Times Cited: 25
Nature’s Arsenal: Harnessing the Capacity of Phytochemicals to Enhance Immune Checkpoint Inhibitor Therapy of Cancers: An Especial Attention to Brain Malignancies
Amir R. Afshari, Mehdi Sanati, Seyed Sajad Ahmadi, et al.
Cancer Letters (2024) Vol. 593, pp. 216955-216955
Closed Access | Times Cited: 5
Thymol has anticancer effects in U-87 human malignant glioblastoma cells
Farid Qoorchi Moheb Seraj, Niloofar Heravi-Faz, Arash Soltani, et al.
Molecular Biology Reports (2022) Vol. 49, Iss. 10, pp. 9623-9632
Closed Access | Times Cited: 21
Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment
Andrea Franson, Brandon L. McClellan, María L. Varela, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 20
Aptamers against cancer drug resistance: Small fighters switching tactics in the face of defeat
Mehdi Sanati, Amir R. Afshari, Seyed Sajad Ahmadi, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2023) Vol. 1869, Iss. 6, pp. 166720-166720
Closed Access | Times Cited: 12
The diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma
Lingyun Zhang, Yu Jiang, Gao Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma
Mohammad Jalili‐Nik, Arash Soltani, Baratali Mashkani, et al.
International Immunopharmacology (2021) Vol. 98, pp. 107870-107870
Closed Access | Times Cited: 25
Zerumbone, a ginger sesquiterpene, inhibits migration, invasion, and metastatic behavior of human malignant glioblastoma multiforme in vitro
Mohammad Jalili‐Nik, Amir R. Afshari, Hamed Sabri, et al.
BioFactors (2021) Vol. 47, Iss. 5, pp. 729-739
Closed Access | Times Cited: 24
Anticancer Mechanisms of Berberine: A Good Choice for Glioblastoma Multiforme Therapy
Bahram Bibak, Farzaneh Shakeri, Zakieh Keshavarzi, et al.
Current Medicinal Chemistry (2022) Vol. 29, Iss. 26, pp. 4507-4528
Open Access | Times Cited: 17
Targeting the Tumor Immune Microenvironment Could Become a Potential Therapeutic Modality for Aggressive Pituitary Adenoma
Zuocheng Yang, Xuemei Tian, Kun Yao, et al.
Brain Sciences (2023) Vol. 13, Iss. 2, pp. 164-164
Open Access | Times Cited: 9
Alpha-Lipoic Acid, Auraptene, and Particularly Their Combination Prevent the Metastasis of U87 Human Glioblastoma Cells
Azam Izadi, Mohammad Soukhtanloo, Farshad Mirzavi, et al.
Evidence-based Complementary and Alternative Medicine (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 9
How do phosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme
Mehdi Sanati, Samaneh Aminyavari, Hamid Mollazadeh, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 2, pp. 323-339
Closed Access | Times Cited: 14
Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments
Jason Thomas Duskey, Arianna Rinaldi, Ilaria Ottonelli, et al.
Pharmaceutics (2022) Vol. 14, Iss. 7, pp. 1450-1450
Open Access | Times Cited: 14
Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles
Armita Mahdavi Gorabi, Mehrnaz Sadat Ravari, Mohammad‐Javad Sanaei, et al.
International Immunopharmacology (2022) Vol. 113, pp. 109300-109300
Closed Access | Times Cited: 13
Combretastatin A-4 suppresses the invasive and metastatic behavior of glioma cells and induces apoptosis in them: in-vitro study
Mostafa Karimi Roshan, Amir R. Afshari, Farshad Mirzavi, et al.
Medical Oncology (2023) Vol. 40, Iss. 11
Closed Access | Times Cited: 7
Glioma-associated mesenchymal stem cells-mediated PD-L1 expression is attenuated by Ad5-Ki67/IL-15 in GBM treatment
Qing Zhang, Junwen Zhang, Peiwen Wang, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Inhibitory Effects of Urolithins, Bioactive Gut Metabolites from Natural Polyphenols, against Glioblastoma Progression
Ching‐Kai Shen, Bor‐Ren Huang, Vichuda Charoensaensuk, et al.
Nutrients (2023) Vol. 15, Iss. 23, pp. 4854-4854
Open Access | Times Cited: 6
The Potential Therapeutic Impact of Metformin in Glioblastoma Multiforme
Mehdi Sanati, Samaneh Aminyavari, Hamid Mollazadeh, et al.
Current Medicinal Chemistry (2022) Vol. 30, Iss. 7, pp. 857-877
Closed Access | Times Cited: 9
Comprehensive bioinformatics analysis of ribonucleoside diphosphate reductase subunit M2(RRM2) gene correlates with prognosis and tumor immunotherapy in pan-cancer
Liyuan Wu, Le Yin, Linxiang Ma, et al.
Aging (2022) Vol. 14, Iss. 19, pp. 7890-7905
Open Access | Times Cited: 9
Autophagy in combination therapy of temozolomide and IFN-γ in C6-induced glioblastoma: role of non-coding RNAs
Hamideh Bashiri, Maryam Moazam-Jazi, Mohammad Reza Karimzadeh, et al.
Immunotherapy (2023) Vol. 15, Iss. 14, pp. 1157-1169
Closed Access | Times Cited: 5
Identification of an N6-methyladenosine (m6A)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas
Zhiqiang Cai, Jianbo Zhang, Ziying Liu, et al.
Annals of Translational Medicine (2021) Vol. 9, Iss. 15, pp. 1241-1241
Open Access | Times Cited: 11
Psidium guajava induces cytotoxicity in human malignant glioblastoma cell line: Role of reactive oxygen species
Azar Hosseini, Mohaddeseh Sadat Alavi, Amir Reza Shahraki, et al.
Toxicology in Vitro (2023) Vol. 89, pp. 105567-105567
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top